• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ORTINLAABS.BO
Share

Ortin Laboratories Limited Stocks

₹ 0Last Updated 23.03.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

₹ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ortin Laboratories Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti-anginal and cardio vascular, and antifungal products. Its formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti retro viral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.08.2026 21:43

A Market That Can't Lose: Michael Burry on What's Preventing Stocks from Falling

04.08.2026 21:26

The S&P 500 and the Dow hit record highs, while Brent crude fell below $80: the market is awaiting a deal with Iran

04.08.2026 19:58

Snap's stock soared: the company expects sales to rise ahead of the launch of its AR glasses

04.08.2026 19:01

Palantir shares jumped 22% at the opening bell following a strong earnings report

04.08.2026 18:05

The "explosive" rise in gold prices is not over — Deutsche Bank

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026